GoKawiil
Eli Lilly Nears Deal for Cancer Biotech
(feeds.content.dowjones.io)
31.
32.
33.
34.
The Radical Cancer Science That Saved My Life
(feeds.content.dowjones.io)
35.
36.
Why workplaces need a gendered health approach
(feeds.feedburner.com)
37.
38.
39.
Aloe Blacc’s fame means nothing in biotech (and that’s the point)
(techcrunch.com)
40.
41.
42.
Early-onset cancer fuels calls for wider screening — but at what cost?
(feeds.nature.com)
43.
Global cancer rates are rising. How are countries reacting?
(feeds.nature.com)
44.
Improving cancer survival rates will require hard policy choices
(feeds.nature.com)
45.
Here are the top locations for cancer research in the Nature Index
(feeds.nature.com)
46.
Four rising stars shaping the future of cancer research
(feeds.nature.com)
47.
48.
Emergence of oncofetal plasticity is ubiquitous in early colorectal cancers
(feeds.nature.com)
49.
Giant cancer study reveals effectiveness of ‘off label’ treatments
(feeds.nature.com)
50.
A mechanism for adaptive genome regulation in cancer
(feeds.nature.com)
51.
Tumour promotion through the lens of evolution
(feeds.nature.com)
52.
53.
The Download: how humans make decisions, and Moderna’s “vaccine” word games
(technologyreview.com)
54.
What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma
(technologyreview.com)
55.
If you want to get something done, hire a cancer patient
(feeds.feedburner.com)
56.
Tumour trap: engineered enhancer sequences enlisted to kill cancer cells
(feeds.nature.com)
57.
58.
Gilead to Buy German Biotech Tubulis for $3 Billion for Experimental Cancer Drugs
(feeds.content.dowjones.io)
59.
New drugs take aim at one of cancer’s deadliest mutations
(feeds.nature.com)